Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02538133
Other study ID # 49RC14_0072
Secondary ID 2015-001342-28
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 2015
Est. completion date January 2020

Study information

Verified date August 2015
Source University Hospital, Angers
Contact HERVE RAKOTONIRINA, Dr
Phone +33(0)241353412
Email HeRakotonirina@chu-angers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vascular Prothesis Infection is a rare but an extremely serious complication. Diagnosis is often difficult (germs are found only in 50% of cases). Conventional imagery is often non-specific and difficult to interpret especially in early postoperative phase. Leukocytes isolated from the patient's blood are labeled with a radiopharmaceutical technetium 99mTc-HMPAO.

The aim of this study is to assess the overall diagnostic performance of scintigraphy (hybrid SPEC-CT) with labeled leucocytes in diagnosis of subdiaphragmatic vascular prothesis infection.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date January 2020
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patient of more than 18 years old

- Patient with a subdiaphragmatic vascular prosthesis

- Vascular prosthesis infection suspected with clinical (flow from the scare and/or local pain and/or erythema and/or persistent fever and/or bacteraemia) and/or biological (inflammatory syndrome : elevated C-reactive protein and/or erythrocyte sedimentation rate (ESR) and/or white blood cells increased) infection signs

- Patient willing to participate with a signed informed consent

- Patient covered by a healthcare insurance

Exclusion Criteria:

- Pregnant women or of childbearing age without effective contraception

- Prosthesis limited to a bare stent.

- Patient who has been committed to an institution by legal or regulatory order

- Contraindications for labeled leukocytes scintigraphy realization :

- Restlessness, inability to keep still lie at least 1 hour

- Claustrophobia

- Poor compliance predictable or impaired general condition making it impossible to carry out the examination

- Refusal to participate in the study

Study Design


Intervention

Biological:
99mTc-Exametazime (HMPAO)-labeled leukocytes
Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection

Locations

Country Name City State
France CHU Angers
France CH Le Mans
France CHRU Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients correctly classified by interpreting scintigraphy for the diagnosis of vascular prosthesis infection. The percentage of patients correctly classified is assessed comparing with the diagnostic established by the expert committee. A visual analysis of scintigraphy for diagnosing vascular prosthesis infection. Scintigraphy is considered positive if at least one abnormal localization is seen at vascular prosthesis and if intensity is increasing over time on 20-24h delayed images. One year after inclusion when vascular prosthesis infection is suspected and hybrid SPEC-CT with labeled leukocytes has been performed.